BRPI0516933B8 - métodos para o isolamento da haptoglobina humana, das isoformas de hp humana individuais, e da albumina e da haptoglobina humana - Google Patents

métodos para o isolamento da haptoglobina humana, das isoformas de hp humana individuais, e da albumina e da haptoglobina humana

Info

Publication number
BRPI0516933B8
BRPI0516933B8 BRPI0516933A BRPI0516933A BRPI0516933B8 BR PI0516933 B8 BRPI0516933 B8 BR PI0516933B8 BR PI0516933 A BRPI0516933 A BR PI0516933A BR PI0516933 A BRPI0516933 A BR PI0516933A BR PI0516933 B8 BRPI0516933 B8 BR PI0516933B8
Authority
BR
Brazil
Prior art keywords
haptoglobin
human
isolating
isoforms
methods
Prior art date
Application number
BRPI0516933A
Other languages
English (en)
Portuguese (pt)
Inventor
Podmore Adrian
Dalton Joan
Kumpalume Peter
Original Assignee
Bio Products Laboratory Ltd
Nhs Blood & Transplant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Products Laboratory Ltd, Nhs Blood & Transplant filed Critical Bio Products Laboratory Ltd
Publication of BRPI0516933A publication Critical patent/BRPI0516933A/pt
Publication of BRPI0516933B1 publication Critical patent/BRPI0516933B1/pt
Publication of BRPI0516933B8 publication Critical patent/BRPI0516933B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Semiconductor Lasers (AREA)
BRPI0516933A 2004-10-19 2005-10-19 métodos para o isolamento da haptoglobina humana, das isoformas de hp humana individuais, e da albumina e da haptoglobina humana BRPI0516933B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0423196.5 2004-10-19
GBGB0423196.5A GB0423196D0 (en) 2004-10-19 2004-10-19 Method
PCT/GB2005/004037 WO2006043062A1 (en) 2004-10-19 2005-10-19 Method for the isolation of haptoglobin

Publications (3)

Publication Number Publication Date
BRPI0516933A BRPI0516933A (pt) 2008-09-23
BRPI0516933B1 BRPI0516933B1 (pt) 2021-02-09
BRPI0516933B8 true BRPI0516933B8 (pt) 2021-05-25

Family

ID=33484812

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516933A BRPI0516933B8 (pt) 2004-10-19 2005-10-19 métodos para o isolamento da haptoglobina humana, das isoformas de hp humana individuais, e da albumina e da haptoglobina humana

Country Status (13)

Country Link
US (1) US9145448B2 (https=)
EP (1) EP1802654B1 (https=)
JP (1) JP4950053B2 (https=)
AT (1) ATE539085T1 (https=)
AU (1) AU2005297061B2 (https=)
BR (1) BRPI0516933B8 (https=)
CA (1) CA2584407C (https=)
ES (1) ES2379157T3 (https=)
GB (1) GB0423196D0 (https=)
IL (1) IL182340A (https=)
MX (1) MX2007004244A (https=)
PL (1) PL1802654T3 (https=)
WO (1) WO2006043062A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
CN112717125A (zh) * 2012-10-03 2021-04-30 瑞士杰特贝林生物制品有限公司 一种纯化蛋白质的方法
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
WO2020160505A1 (en) * 2019-02-01 2020-08-06 Ohio State Innovation Foundation Methods of protein purification
EP3972646A4 (en) * 2019-05-20 2023-06-14 Ohio State Innovation Foundation APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USE THEREOF
US20240034749A1 (en) * 2021-02-04 2024-02-01 Green Cross Corporation Method for purification of hemopexin and haptoglobin
CN115531921B (zh) * 2022-08-26 2024-07-16 大连依利特分析仪器有限公司 一种制备型液相色谱馏分收集装置及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1426039A (en) 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
US4061735A (en) * 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
JPS5337406B2 (https=) * 1973-11-15 1978-10-09
US4137307A (en) * 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
JPS52128205A (en) * 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
JP3554796B2 (ja) 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
JP3825061B2 (ja) * 1994-09-28 2006-09-20 三菱ウェルファーマ株式会社 ハプトグロビンの製造方法
DE19960500A1 (de) * 1999-12-15 2001-07-12 Giesing Michael Antikörper und Verfahren zu ihrer Herstellung, deren Verwendung sowie Immunisierungscocktails, Immunoassay-Sets und Peptide
AU2002210383A1 (en) * 2000-10-16 2002-04-29 Proteopharma Aps The function of a haptoglobin-haemoglobin receptor and the uses thereof
US20030113830A1 (en) 2001-07-11 2003-06-19 Rappaport Family Institute For Research In The Medical Sciences Novel antioxidant, nucleic acid constructs encoding same, pharmaceutical compositions containing same and use of same for reducing oxidative-stress
JP2004244348A (ja) * 2003-02-13 2004-09-02 Nihon Pharmaceutical Co Ltd パプトグロビンの精製法
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
WO2006107708A1 (en) 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin

Also Published As

Publication number Publication date
CA2584407C (en) 2015-02-03
JP2008517046A (ja) 2008-05-22
EP1802654B1 (en) 2011-12-28
PL1802654T3 (pl) 2012-05-31
US20090281282A1 (en) 2009-11-12
BRPI0516933A (pt) 2008-09-23
EP1802654A1 (en) 2007-07-04
MX2007004244A (es) 2007-09-07
IL182340A0 (en) 2007-07-24
JP4950053B2 (ja) 2012-06-13
CA2584407A1 (en) 2006-04-27
WO2006043062A1 (en) 2006-04-27
AU2005297061A1 (en) 2006-04-27
ES2379157T3 (es) 2012-04-23
IL182340A (en) 2012-06-28
AU2005297061B2 (en) 2011-09-01
BRPI0516933B1 (pt) 2021-02-09
ATE539085T1 (de) 2012-01-15
GB0423196D0 (en) 2004-11-24
US9145448B2 (en) 2015-09-29

Similar Documents

Publication Publication Date Title
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
BRPI0610108B8 (pt) compostos promotores de apoptose e composição que compreende os ditos compostos
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
BRPI0514259A (pt) proteìna de fusão de domìnio de ligação
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
ATE511840T1 (de) Imidazolderivate als entzündungshemmende mittel
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
NO20072599L (no) Inhibitorer av 11-beta-hydroksyl steroid dehydrogenase Type 1 og fremgangsmater for anvendelse derav
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
DE602005023763D1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
BRPI0920572A8 (pt) Inativação viral durante a purificação dos anticorpos
NO20016007L (no) Rekombinant anti-CD40-antistoff og anvendelser derav
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
NO20070067L (no) Pyrrolopyridinderivater
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIO PRODUCTS LABORATORY LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.